A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.


Updates from The Motley Fool

Latest updates on Geron from Fool.com.  The Fool has written over 200 articles on Geron.
3 Top Stocks Under $5

These stocks may have a low single-digit share price, but that may change soon enough.

3 Top Biotech Stocks Under $5

Shares of Geron Corporation, Rigel Pharmaceuticals Inc., and Agenus Inc. appear to be trading for...



Stock Performance

View Interactive GERN Charts
Sponsored by

Key Data Points

Primary metrics and data points about Geron.
Current Price: $2.02
Prev Close: $1.99
Open: $2.00
Bid: $2.02
Ask: $2.08
Day's Range: $1.99 - $2.07
52wk Range: $1.81 - $3.15
Volume: 901,041
Avg Vol 1,267,729
Market Cap: $322M
P/E (ttm): -11.06
EPS (ttm): ($0.18)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Geron.
CAPS Rating 2 out of 5
 
648 Outperform
62 Underperform
CAPS All Stars
 
82 Outperform
20 Underperform

How do you think Geron will perform against the market?



You pick for Geron is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

John A. Scarlett, CEO

73% Approve

Based on 4 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Geron.

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers